Ironshore Pharma names new president and COO

Ironshore Pharmaceuticals, a wholly-owned subsidiary of Canada’s Highland Therapeutics, has appointed Scott Evangelista to the position of president and chief operating officer (COO).

Prior to joining Ironshore, Mr Evangelista was president of integrated engagement services at Quintiles (now IQVIA), where he was responsible for the outsourced commercial businesses that supported companies in launching and growing their pharmaceutical brands.

Commenting on the appointment, David Lickrish, Highland’s chairman and chief executive, stated: “Scott brings a unique perspective to the launch of new drugs gained from decades of experience providing front-line commercialization support to a variety of companies at various stages of growth. His unique skills and insight will help Ironshore be nimble and innovate in a rapidly evolving US market as we prepare to launch our first drug. We believe Jornay PM is an important treatment option for ADHD patients and the physicians who treat them, and we are thrilled to welcome Scott to the Senior Leadership Team at Ironshore to help support its launch in 2019.”